Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina

被引：0

作者：

Edgar Carnero Contentti

Pablo A. López

Agustín Pappolla

Ricardo Alonso

Berenice Silva

Norma Deri

María E. Balbuena

Marcos Burgos

Geraldine Luetic

Amelia Alvez Pinheiro

Mariela Cabrera

Javier Hryb

Pedro Nofal

Claudia Pestchanker

Carlos Vrech

Darío Tavolini

Verónica Tkachuk

Gisela Zanga

Mariano Marrodan

María Célica Ysrraelit

Jorge Correale

Adriana Carrá

Belén Federico

Orlando Garcea

Nora Fernandez Liguori

Liliana Patrucco

Edgardo Cristiano

Diego Giunta

Marina Alonso Serena

Juan I. Rojas

机构：

[1] Neuroimmunology Unit,Department of Neurosciences

[2] Hospital Aleman,Servicio de Neurología

[3] Hospital Italiano de Buenos Aires,Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología

[4] Hospital Ramos Mejía,Servicio de Neurología

[5] Centro Universitario de Esclerosis Múltiple,Servicio de Neurología

[6] Sanatorio Güemes,Neurology Department

[7] Centro de Investigaciones Diabaid,Departamento de Neurología

[8] Hospital Fernandez,Departamento de Neurología

[9] Hospital de Clínicas José de San Martín,Servicio de Clínica Médica

[10] Hospital San Bernardo,Servicio de Neurología

[11] Instituto de Neurociencias de Rosario,undefined

[12] Hospital San Martín,undefined

[13] Hospital Militar Campo de Mayo,undefined

[14] Hospital Carlos G Durand,undefined

[15] Hospital de Clínicas Nuestra Señora del Carmen,undefined

[16] Hospital Central Dr. Ramon Carrillo,undefined

[17] Departamento de Enfermedades Desmielinizantes,undefined

[18] INECO Neurociencias Oroño,undefined

[19] Hospital Cesar Milstein,undefined

[20] FLENI,undefined

[21] Sección de Enfermedades Desmielinizantes,undefined

[22] Hospital Británico,undefined

[23] Hospital Universitario Fundación Favaloro,undefined

[24] Novartis SRL,undefined

[25] Centro de Esclerosis Múltiple de Buenos Aires,undefined

[26] Hospital Italiano de Buenos Aires,undefined

[27] Unidad de EM y Enfermedades Desmielinizantes,undefined

[28] Hospital Universitario de CEMIC,undefined

来源：

Neurological Sciences | 2024年 / 45卷

关键词：

Multiple sclerosis; COVID-19; Vaccines; Argentina; Incidence; High-efficacy therapies;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：379 / 389

页数：10

共 285 条

[1]

Achiron A(2021)COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021 Mult Scler 27 864-870

[2]

Dolev M(2019)Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JAMA 321 175-187

[3]

Menascu S(2022)COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection J Biomed Sci 29 82-5394

[4]

Zohar DN(2022)Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion J Neurol 269 5382-980

[5]

Dreyer-Alster S(2019)Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis Lancet Neurol 18 973-137

[6]

Miron S(2019)The Argentinean multiple sclerosis registry (RelevarEM): methodological aspects and directions Mult Scler Relat Disord 32 133-507

[7]

Shirbint E(2021)Efficacy classification of modern therapies in multiple sclerosis J Comp Eff Res 10 495-2111

[8]

Magalashvili D(2022)Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies Mult Scler 28 2106-100

[9]

Flechter S(2021)Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies EBioMedicine 72 103581-173

[10]

Givon U(2022)COVID-19 vaccine response in people with multiple sclerosis Ann Neurol 91 89-306

← 1 2 3 4 5 6 7 8 9 10 →